Pavan Asalapuram

Pavan Asalapuram

Affiliated to Research

Global health researcher and translational scientist advancing diagnostics, AMR, One Health innovation, and scalable solutions for high-burden infectious diseases.

Visiting address: Widerströmska huset Tomtebodavägen 18 A, plan 3, 17165 Solna
Postal address: K9 Global folkhälsa, K9 GPH Stålsby Lundborg, 171 77 Stockholm

About me

  • I am a global health researcher, innovator, and translational scientist with more than two decades of experience in developing and advancing technologies for high-burden infectious diseases and antimicrobial resistance. My work is driven by a commitment to equitable, science-based solutions for drug-resistant zoonotic and community-spread infections, oral health, and other conditions that place a substantial burden on populations and health systems globally.

    My academic and professional journey has focused on translating scientific knowledge into technologies that are not only innovative, but also clinically relevant, operationally feasible, and scalable across diverse healthcare settings. I have led the development of few diagnostic and hygiene platforms including mfloDx™, RAR-ELISA™, SelektaDx™, SteriPOC™, InstaCoat™, and OralAura™, with applications spanning MDR-TB, AMR, oral health, cancer-related needs, and veterinary infections, towards One Health framework.

    In parallel, I have coordinated multi-country research and innovation projects, established ISO-certified production facilities in Asia, conducted multi-country clinical evaluations, supported commercialization pathways, and coordinated the introduction of products into the market. My work has been advanced through collaborations and projects supported by major funding agencies in Europe, India, and USA. My innovation portfolio includes 10 patent families and 15 trademarks with international patent protection pursued through WIPO/PCT routes.

Research

  • My broader research and innovation interests lie at the forefront of diagnostics, One Health, implementation science, health systems, policy, and AI-enabled global health innovation. I am particularly interested in how advanced scientific and technological approaches can be translated into accessible, scalable, and sustainable solutions for infectious diseases, antimicrobial resistance, and other high-burden public health challenges. My work is grounded in the belief that transformative progress in global health depends on combining scientific innovation with strong partnerships, systems thinking, implementation pathways, and policy relevance. Through this integrated approach, I aim to help shape the next generation of technologies and strategies that connect discovery, data, and real-world impact across diverse populations and settings.

Teaching

  • I have supervised approximately 20 Bachelor’s and Master’s thesis students and projects, taught laboratory practical courses at undergraduate and postgraduate levels, and delivered capacity-building workshops for clinicians and policymakers from India and China at the intersection of innovation, policy, and global health.

Articles

All other publications

  • Published conference paper: INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY. 2026;S8(Special Issue 2026 – Abstracts):S8
    Pavan A; Nikhil S; Vasim A; Narayanan M; Stålsby Lundborg C
  • Patent: 2025
    Portable and adaptive modular sterilization and lubrication system and applications
    Asalapuram P
  • Patent: 2025
    One-Step Intercepting polymerase chain reaction (IntPCR) for simultaneous detection of wildtypes and selective point mutations and applications thereof
    Asalapuram P; Nikhil S
  • Patent: 2025
    Analytical, clinical and interdisciplinary applications utilizing Shigella flexneri apyrase
    Asalapuram P
  • Patent: 2024
    Novel coating and immobilization buffer for antigens and antibodies and uses thereof
    Asalapuram P; Nikhil S; Krishnan S
  • Patent: 2022
    Modified Shigella apyrase and uses thereof
    Asalapuram P; Nikhil S
  • Patent: 2017
    Diagnostic device and related method
    Asalapuram P; Mats NB
  • Patent: 2016
    Analytical and diagnostic methods utilizing Shigella flexneri apyrase
    Asalapuram P; Aman R
  • Patent: 2009
    A method to detect the microbial resistance to antibiotics using fluorescence
    Asalapuram P; Krishnan S; Alagumaruthanayagam A
  • Review: FOOD TECHNOLOGY AND BIOTECHNOLOGY. 2008;46(2):125-145
    The Need and New Tools for Surveillance of Escherichia coli Pathogens
    Asalapuram P; Krishnan Sankaran
  • Report: 2005;:26
    Characterization of diarrhoeagenic E. coli (EPEC and EHEC) from incidences of infantile diarrhoea
    Asalapuram P

Grants

  • Exploring mlfoDx MDR-TB diagnostic platform in Africa and Latin American markets
    Business Sweden
    1 November 2023
  • Rapid Affordable Reliable-ELISA (RAR-ELISA) platform for the diagnosis of important helminthic infections
    Department of Biotechnology , Ministry of Science and Technology
    1 June 2023 - 31 December 2024
  • Multiplex Diagnostic Platform for Accurate and Rapid Detection of MDR & pre-XDR-TB
    IPE Global
    1 January 2023
  • Adaptable multi-flow diagnostics for multidrug-resistant TB using tongue swabs
    Bill and Melinda Gates Foundation
    1 November 2022
  • AdvanceTB: Towards an improvement in diagnostics and treatment strategies for tuberculosis control
    1 September 2022 - 30 September 2026
    Tuberculosis (TB) was the leading cause of mortality from an infectious disease globally before Coronavirus Disease 19. The unprecedented pandemic is a major setback for TB programmes and its impact has been tremendous in terms of disruption of timely diagnostic and intervention services, drop in notification numbers, treatment interruptions, inadequate patient’s treatment follow-up and increase in mortality. In order to mitigate this impact more efforts and resources have to be allocated. Currently, no COST Action exists to address the complexity of TB management, offering an advantage to this proposal. The ADVANCE-TB is a research network that offers opportunities for collaboration between clinicians, academic researchers from interdisciplinary backgrounds, industry and non-governmental organizations to achieve breakthroughs difficult to obtain by individual partners, allowing a better understanding of the underlying host-pathogen mechanisms, enabling the transfer of basic science into innovative applications and allowing product development and clinical validation. The Action focuses on 1).developing best clinical practices and experimental standardization protocols, including harmonized biobanking procedures
    2).stimulating the development and optimization of products for diagnostic and therapy/monitoring
    3).disseminate knowledge and allow capacity-building through different types of workshops, training schools and short-term scientific missions, prioritizing early career investigators. The tasks are distributed in 4 working groups (WG). Briefly, WG1 will be focused on the characterization of patient’s cohorts, WG2 will be devoted to the development and evaluation of novel diagnostic methods, WG3 will be centred on the design of novel therapeutical strategies and WG4 will be responsible for dissemination and communication activities.
  • mfloDx: An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection
    European Commission Directorate-General for Research and Innovation
    1 January 2020 - 30 June 2024
  • mfloDx: An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection
    European Commission Directorate-General for Research and Innovation
    1 October 2019 - 29 February 2020
  • RCA-ADT diagnostic platform for the rapid detection of enteric pathogens
    EPSRC grant
    1 January 2016 - 31 December 2017
  • A multiplex diagnostic test for multi-drug/extensively drug-resistant tuberculosis
    VINNOVA
    1 November 2013 - 30 September 2016
  • INNOVA4TB: Innovative development to enable individualised tuberculosis treatment
    European Commission Directorate-General for Research and Innovation
  • Integrated fluidic-array-microsystem for rapid screening of extended spectrum β-lactamases and multidrug resistant pathogens.
    KTH - Life Science Platform
  • Real-time wireless biosensor networks for the surveillance of microbes and pollutants in drinking water supply lines
    KTK Life Science Technology Platform

Employments

  • Affiliated to Research, Department of Global Public Health, Karolinska Institutet, 2022-
  • Affiliated to Research, Department of Global Public Health, Karolinska Institutet, 2024-2026
  • CEO, Mitti Lifetek AB, 2019-2024
  • Founder & CEO, EMPE Diagnostics AB, 2016-2024
  • Postdoctor, Stockholm University, 2013-2016
  • Researcher, Biothema AB & KTH, 2012-2013
  • Postdoctor, Molecular Diagnostics, Royal Institute of Technology, 2010-2011

Degrees and Education

  • PhD, Clinical Biotechnology, Anna University, Chennai, 2010
  • M.S. (res), Clinical Biotechnology, Anna University, Chennai, 2006
  • EPGD in Hospital & Health Care Management, Loyola Institute of Business Administration (LIBA), 2002
  • B. Pharmacy, Pharmacy, Madras Medical College, Dr MGR Medical University, 2001

News from KI

Events from KI